SimBioSys has partnered with General Inception, a global company Igniter, to reduce the time and cost associated with oncology drug development using AI and biophysical modeling. The partnership aims to leverage the capabilities of PhenoScope, a tool engineered by SimBioSys to analyze extensive multi-modal data and yield unprecedented insights in cancer drug discovery and development.

The partnership aims to deliver more effective, personalized cancer treatments by allowing all new oncology drug incubations under General Inception to employ SimBioSys' PhenoScope platform. The technology will enable accelerated target identification, credentialing, and clinical positioning, reducing the time span to the clinic. Improved efficacy through patient stratification and precision methodology are also anticipated benefits.

SimBioSys is a TechBio company committed to revolutionizing precision medicine and cancer care. The company integrates AI, data science, and spatial biophysics to develop technologies that offer individualized cancer therapy solutions. Its flagship technology, TumorScope, simulates a patient's tumor in 3D to predict responses to various therapies, facilitating personalized treatment planning. This approach helps clinicians make informed decisions quickly, enhancing patient care.